Current Alzheimer Research

Gong-Ping Liu received his PhD in Labor and environmental health from Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China. He then received postdoctoral training in the laboratory of Prof. Jian-Zhi Wang during which he focused on the molecular mechanisms and gene therapy for neurodegenerative disorders. Dr. Liu joined the Pathophysiology faculty at Huazhong University of Science and Technology as a lecturer in 2008. In 2013, he was hired as a professor at Huazhong University of Science and Technology of the Pathophysiology faculty.

Shaohua Wang is a Chief Physician and a Professor at the Department of Endocrinology at ZhongDa Hospital of Southeast University. He received his M.D. in Clinical Medicine from Nanjing Railway Medical College and Ph.D. in Internal Medicine from Medical School of Southeast University. Professor Wang is an Associate Editor of “Journal of Alzheimer’s Disease”. He has published more than 50 academic papers in the scientific database. His research is primarily focused on the basic and clinical study of diabetic associated-cognitive impairment, prevention and treatment strategies of diabetic chronic complications as well as prevention and early intervention strategies of gestational diabetes mellitus. He is currently working to provide additional insights into the pathogenesis of T2DM-related cognitive impairment and an early therapeutic strategy to treat dementia.

Dr. Huafeng Wei is an Associate Professor with Tenure at the Department of Anesthesiology at the University of Pennsylvania in the U.S.A. Dr. Wei completed his medical graduate student education and training in Anesthesiology at Tongji Medical University in 1988. He obtained his Ph.D. in pharmacology and toxicology from the George Washington University in 1996 and completed his postdoctoral training at Georgetown University and National Institute of Health (NIH) in 1999. He completed his second resident training in Anesthesiology and Critical Care at the University of Pennsylvania in 2003 and become a standing faculty member thereafter at UPENN. His lab has focused on studying the role of calcium dysregulation in neurodegeneration in various neurodegenerative diseases, especially in Alzheimer’s disease and after various general anesthetics treatments. His lab is the first to demonstrate that dantrolene, a drug for treatment of malignant hyperthermia, can abolish the memory and learning impairment in various animal models of Alzheimer’s disease. Dr. Wei has been an invited speaker for Harvard, Johns Hopkins, UCSF, Duke, UVA, Imperial College of England, University of Heidelberg in Germany, University of Padova in Italy, as well as speakers for international conferences in more than 10 countries and regions.

Prof. Shengzhou Wu received a degree of bachelor of Medicine from Shanghai Medical University (renamed as Shanghai Medical College of Fudan University in 2000) and obtained a Ph.D degree in Neuroscience from University of Arkansas for Medical Science. After a postdoctoral fellowship in Department of Neurology in Washington University School of Medicine in St Louis he has joined and currently is a professor in School of Optometry and Ophthalmology, Wenzhou Medical University in China. His major scientific interest is focused on neurodegeneration in the central nervous system and in the retina including Alzheimer's disease.